Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT05029960
EARLY_PHASE1
Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas
Sponsor: University of Rochester
View on ClinicalTrials.gov
Summary
The purpose of this study is to determine whether the study medication, brivaracetam, is tolerable and safe for patients with brain tumors.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2022-05-17
Completion Date
2025-08-31
Last Updated
2024-08-09
Healthy Volunteers
No
Conditions
Interventions
DRUG
Brivaracetam
Dose of 50 mg twice daily for 6 months
Locations (1)
University of Rochester Medical Center
Rochester, New York, United States